von Herrath D, Hüfler M, Hartenstein-Koch K, Kutschera D, Schaefer K, Dati F
Medizinische Abteilung II, St.-Joseph-Krankenhaus I, Berlin, FRG.
Blood Purif. 1988;6(2):106-10. doi: 10.1159/000169491.
Chronic hemofiltration (HF) is now a well-established method, especially for elderly uremic patients and those suffering from cardiovascular problems. This is due to the fact that chronic HF offers superior treatment comfort with less hypotensive episodes, vomiting, muscle cramps and febrile reactions. Apart from the different blood purification techniques involved in chronic HF compared to hemodialysis (i.e. convection versus diffusion), it might well be that the better treatment comfort is attributable to a certain extent to the polyamide HF membrane used in our HF treatments. We studied different biocompatibility parameters and received the following data: (a) leukocytes and thrombocytes remained unchanged during a treatment session; (b) elastase increased slightly but there was no difference between the polyamide and polycarbonate membrane, and (c) arterial and venous concentrations of C5a and C3d remained almost unchanged. The superior treatment comfort and better vascular stability of HF over hemodialysis might also be due to the improved biocompatibility of the applied hemofilter as the polyamide membrane induces no changes in different biocompatibility parameters such as leukocytes, thrombocytes, C5a or C3d.
慢性血液滤过(HF)如今已是一种成熟的方法,尤其适用于老年尿毒症患者以及患有心血管疾病的患者。这是因为慢性血液滤过提供了更高的治疗舒适度,低血压发作、呕吐、肌肉痉挛和发热反应较少。除了与血液透析相比,慢性血液滤过涉及不同的血液净化技术(即对流与扩散)之外,更好的治疗舒适度在一定程度上可能归因于我们血液滤过治疗中使用的聚酰胺血液滤过膜。我们研究了不同的生物相容性参数并得到以下数据:(a)在一次治疗过程中白细胞和血小板保持不变;(b)弹性蛋白酶略有增加,但聚酰胺膜和聚碳酸酯膜之间没有差异,以及(c)C5a和C3d的动脉和静脉浓度几乎保持不变。与血液透析相比,血液滤过具有更高的治疗舒适度和更好的血管稳定性,这也可能归因于所应用血液滤过器生物相容性的改善,因为聚酰胺膜不会引起白细胞、血小板、C5a或C3d等不同生物相容性参数的变化。